| 摘要 |
<p>PCT No. PCT/US96/00020 Sec. 371 Date Jun. 20, 1997 Sec. 102(e) Date Jun. 20, 1997 PCT Filed Jan. 16, 1996 PCT Pub. No. WO96/23760 PCT Pub. Date Aug. 8, 1996Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of Formula I: wherein R1 and R2 are independently H, C1-8 alkyl or C1-8 alkylAryl; X is CH2R3 or NHSO2R4; Y is hydrogen, CH2R3, NHSO2R4, CONR1R2, SO2NR1R2, SO2CH3, halogen, OSO2CF3, SCH3 or OCH3; R3 is NHSO2R4, SO2R4, CONR1R2 or Aryl; and R4 is NR1R2, C1-C8 alkyl, Aryl or C1-C8 alkylAryl.</p> |
